The role of the tumor microenvironment of pancreatic cancer to predict treatment outcome - Microenvironment of pancreatic cancer (MIPA)

Academisch Medisch Centrum0 个研究点目标入组 95 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•* Patients with pancreatic tumors, with histological or cytological proof of adenocarcinoma or a high suspicion on CT imaging.
•* Tumor size * 1cm.
•* WHO-performance score 0-2.
•* Scheduled for surgery or neo-adjuvant chemotherapy/radiation followed by surgery. For the reproducibility part of the study, patients who will not undergo surgery, may be included, too.
•* Written informed consent.

•* Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol.
•* Contra-indications for MR scanning, including patients with a pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; or a non-MR compatible aneurysm clip in their brain; patients with severe claustrophobia.
•* Renal failure (GFR < 30 ml/min) hampering safe administration of Gadolinium containing MR contrast agent.
•* For the reproducibility part of the protocol: surgery, radiation and/or chemotherapy foreseen within the timeframe needed for MR scanning.

发起方